Abstract: Provided is a peptide composition for preventing or treating Alzheimer's dementia. A peptide or a salt substituent thereof according to the presently claimed subject matter exhibits effects such as suppression of LPS-mediated cytokine production, suppression of LPS-induced neuroinflammation, amelioration of cognitive impairment, suppression of beta amyloid or tau protein aggregation, and suppression of neuronal loss. The polypeptide or the salt substituent thereof can permeate the blood-brain barrier, and thus, is expected to be usefully used for preventing or treating Alzheimer's dementia.

Abstract: The present invention relates to a production method of a composition that can prevent, ameliorate, or treat autoimmune diseases including allergic diseases, and the composition produced by the method. In the method, the plasmacytoid dendritic cells with tolerogenic capacity may be induced from the immature dendritic cells at a high yield using a simple and easy process. The plasmacytoid dendritic cells can effectively prevent, ameliorate or treat the autoimmune diseases.

Abstract: The present invention relates to a production method of a composition that can prevent, ameliorate, or treat hypersensitivity immune diseases including allergic diseases, and the composition produced by the method. In the method, the plasmacytoid dendritic cells with tolerogenic capacity may be induced from the immature dendritic cells at a high yield using a simple and easy process. The plasmacytoid dendritic cells can effectively prevent, ameliorate or treat the hypersensitivity immune diseases.

Abstract: The present invention relates to a pharmaceutical composition for treating and preventing inflammatory diseases comprising an ethyl acetate fraction of dried extract of Trachelospermi caulis as an active ingredient and a method for producing the fraction. More particularly, the present invention relates to a composition for preventing and treating inflammatory diseases comprising an ethyl acetate fraction of dried extract of Trachelospermi caulis as an active ingredient, in which the extract of Trachelospermi caulis is refined and concentrated to contain 0.05˜12% by weight of arctigenin as an index material, and a method for producing the fraction.

Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of inflammatory diseases comprising a mixture of herbal extracts of Trachelospermi caulis and Pyrola japonica as active ingredients. More particularly, the pharmaceutical composition of the present invention comprises a mixture of herbal extracts of Trachelospermi caulis and Pyrola japonica in a predetermined range thereby exhibiting superior on therapeutic effects for the treatment of pains, acute inflammation, secretion of enzymes associated with factors inducing inflammation, and production of NO, iNOS, etc., as compared to those prepared from single herbal drugs, thus being useful in the prevention and treatment of inflammatory diseases such as arthritis.

Abstract: The present invention relates to a pharmaceutical composition for treating and preventing inflammatory diseases comprising an ethyl acetate fraction of dried extract of Trachelospermi caulis as an active ingredient and a method for producing the fraction. More particularly, the present invention relates to a composition for preventing and treating inflammatory diseases comprising an ethyl acetate fraction of dried extract of Trachelospermi caulis as an active ingredient, in which the extract of Trachelospermi caulis is refined and concentrated to contain 0.05˜12% by weight of arctigenin as an index material, and a method for producing the fraction.

Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of inflammatory diseases comprising a mixture of herbal extracts of Trachelospermi caulis and Pyrola japonica as active ingredients. More particularly, the pharmaceutical composition of the present invention comprises a mixture of herbal extracts of Trachelospermi caulis and Pyrola japonica in a predetermined range thereby exhibiting superior on therapeutic effects for the treatment of pains, acute inflammation, secretion of enzymes associated with factors inducing inflammation, and production of NO, iNOS, etc., as compared to those prepared from single herbal drugs, thus being useful in the prevention and treatment of inflammatory diseases such as arthritis.

Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of inflammatory diseases comprising The present invention relates to a pharmaceutical composition for the prevention and treatment of inflammatory diseases comprising Trachelospermi caulis extract as an active ingredient. More particularly, the pharmaceutical composition of the present invention is characterized in that it is standardized and formulated so that the arctiin is contained in the Trachelospermi caulis extract within a predetermined range to exhibit excellent inhibitory effects on pains, acute inflammation, acute edema, production of iNOS, and TNF-Yá, activation of the enzymes of MAP kinases and NFYêB, thus effective in the prevention and treatment of inflammatory diseases such as arthritis.

Abstract: A thiazole compound represented by general formula (I), wherein R is hydrogen atom, a hydroxy group, a straight or branched C.sub.1 -C.sub.6 lower alkyl group, a C.sub.1 -C.sub.4 lower alkoxy group, phenyl group, a phenyl group having one to three substituents selected from a group consisting of a C.sub.1 -C.sub.4 lower alkyl group, a C.sub.1 -C.sub.4 lower alkoxy group, fluorine, chlorine, bromine and an amino group, a C.sub.1 -C.sub.5 alkylphenyl group, a phenyl group having one to three substituents selected from a group consisting of a C.sub.1 -C.sub.4 lower alkyl group, a C.sub.1 -C.sub.4 lower alkoxy group, fluorine, chlorine, bromine and an amino group, a substituted or unsubstituted guanidino group, or an amino group having a general formula: NR.sub.3 R.sub.4 in which R.sub.3 and R.sub.4, identical to or different from each other, represent independently a hydrogen atom, a C.sub.1 -C.sub.6 lower alkyl group, a C.sub.3 -C.sub.

Abstract: Novel 4-amino-3-acylnaphthyridine derivatives represented by formula (I), wherein R.sub.1 is hydrogen, C.sub.1 -C.sub.6 lower alkyl group, C.sub.1 -C.sub.6 lower alkoxy group, C.sub.1 -C.sub.6 lower alkoxyalkyl group, C.sub.3 -C.sub.6 cycloalkyl group, C.sub.3 -C.sub.6 cycloalkyl C.sub.1 -C.sub.6 alkyl group, a or phenyl group which maybe substituted with C.sub.1 -C.sub.6 alkyl group; R.sub.2 is hydrogen, C.sub.1 -C.sub.6 lower alkyl group, C.sub.1 -C.sub.6 alkoxy group, C.sub.1 -C.sub.6 alkylthio group, or a group of the formula: NR.sub.6 R.sub.7 wherein R.sub.6 and R.sub.7, identical to or different from each other, are independently hydrogen or C.sub.1 -C.sub.6 lower alkyl group, or R.sub.6 and R.sub.7 may form together 5-membered or 6-membered cycloalkyl group; R.sub.3 is hydrogen, C.sub.1 -C.sub.6 lower alkyl group, C.sub.1 -C.sub.6 alkoxy group, C.sub.1 -C.sub.6 alkylthio group, an amino group substituted with one or two C.sub.1 -C.sub.6 alkyl groups, halogen, cyano group, C.sub.1 -C.sub.

Abstract: The present invention relates to novel pharmaceutical composition for skin diseases, in particular to novel pharmaceutical composition useful for treatment of skin diseases; e.g. burns, wounds, general operative wounds, pernio, decubitus, folliculitis, impetigo, intertrigo, radiation ulcer, acne vulgaris or infectious eczematous dermatitis comprising deproteinized dialysate of calf's blood with tissue regenerative activity and aminoglycoside antibiotic with bacterial infection inhibitory activity as active ingredients.